Copley Scientific, the world’s leading manufacturer and supplier of inhaler testing equipment has acquired Novi Systems, a company with market-leading expertise in the automation of inhaler testing, extending the Copley product range and securing a broader platform for the development of new inhaler testing solutions.

‘We’ve known and respected Novi for many years,’ said Mark Copley, CEO, Copley Scientific, ‘and the two companies are highly complementary with a strong set of shared values. Like Copley, Novi is a UK-based family business, with a ‘can do’ problem solving approach and a reputation for engineering excellence. I’m particularly looking forward to working with Adam Smith who will head up the Automation Division at Copley Scientific, as we continue to develop and evolve our range of advanced inhaler testing solutions. Our combined strengths will undoubtedly provide customers of both companies with new opportunities to streamline and enhance their inhaler testing capabilities.’

Founded in 1993, Novi designs and manufactures modular and integrated systems for the automation of inhaler testing, including the IctusTM automated Andersen Cascade Impactor, with an impressive 25-year heritage. The well-established Vertus® products are flexible, automated shake, fire and flow control systems for delivered dose uniformity and cascade impactor testing of metered-dose inhalers (MDIs), while the DecaVertus® sets the benchmark for automated fire to waste, handling up to ten conventional or breath-actuated MDIs at a time. Both systems enhance the integrity and reproducibility of MDI test data, at the same time reducing the manual labour associated with shaking and firing; the former having recently been enhanced to measure shot weight and for use with nasal sprays.

‘The Copley name is synonymous with inhaler testing and we are delighted to be joining such a strong company,’ said Malcolm Smith, Founder and Managing Director of Novi Systems. ‘Our businesses share a commitment to exemplary customer service and I’m particularly pleased that Novi customers will benefit from an extended knowledge base, as well as a broader global distribution and support network. Mark has a clear vision for Copley Scientific and we’re looking forward to being part of a very bright future.’

Copley supplies equipment for testing MDIs, dry powder inhalers, nebulisers and nasal sprays, including apparatus required by the international pharmacopoeias and regulatory bodies for aerodynamic particle size distribution and delivered dose uniformity measurements. Founded over 70 years ago the company has signalled significant expansion over the course of the last year with a series of senior level appointments and a doubling in size of the Nottingham headquarters. Novi will join and fully integrate with the current Copley team in this newly opened building later this year.

more news from copley scientific